Tsinghua University Selects FEI’s Titan Krios Cryo-Electron Microscope
News Aug 26, 2009
FEI Company has announced that it has successfully completed the installation of its Titan Krios™ cryo transmission electron microscope (TEM) at Tsinghua University in Beijing, China.
The acquisition of this advanced, multi-million dollar microscope, which is the first Titan Krios to be installed in Asia, underscores Tsinghua University’s commitment to leadership in structural biological imaging.
“The Titan Krios’ unique capabilities in automation, cryogenic sample handling and low dose imaging are essential for the advanced structural biological research we pursue here,” said Yigong Shi, professor and senior vice dean of the Medical School at Tsinghua University. “We are confident that it will play a key role in our efforts to unravel the structure-function relationships of biological systems down to the molecular level.”
“We are delighted to complete this first installation of a Titan Krios at Tsinghua University,” said Don Kania, FEI's president and CEO. “We will soon complete additional installations at the Institute of Biophysics of the Chinese Academy of Sciences and at National University of Singapore. The selection of the Titan Krios by these three leading structural biology research institutions further reinforces the instrument’s position as the most advanced, commercially-available TEM solution for structural biological applications. Furthermore, these installations clearly demonstrate the structural biology community’s adoption in Asia of the Titan Krios as a 3D molecular imaging platform of choice.”
The Titan Krios provides a high resolution 3D imaging solution which is specifically designed to image biological structures down to the molecular level in structural biology applications. Its integrated cryogenic sample handling robotics offer improved automation over existing cryogenic TEMs, and the solution permits a full range of high resolution and 3D techniques including: cryo electron microscopy; single particle analysis; and dual-axis tomography of frozen hydrated samples, such as cells.
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE